United States Drug Patent 7,998,506: Claim Scope, Niaspan Patent Landscape and Generic Entry Risk

U.S. Patent No. 7,998,506 protects a specific once-daily evening or nighttime regimen for sustained-release nicotinic acid, commonly known as niacin, in 375 mg, 500 mg, 750 mg, or 1,000 mg dosage units. The claims combine formulation composition, dosing schedule, total daily dose, and lipid-response requirements. The patent does not broadly cover all niacin products or all hyperlipidemia treatments.

The principal commercial relevance is to extended-release niacin products modeled on NIASPAN, including products containing hydroxypropyl methylcellulose, povidone, and stearic acid. The patent is a method-of-treatment patent, so infringement analysis focuses on the labeled or induced use of a qualifying product rather than solely on the product’s composition.

What does U.S. Patent 7,998,506 protect?

The patent claims a method for treating hyperlipidemia by administering a sustained-release solid oral dosage form once per day in the evening or at night.

Each independent claim requires all of the following elements:

Required element	Claims 1-4
Disease or condition	Hyperlipidemia
Active ingredient	Nicotinic acid
Dosage form	Sustained-release solid oral dosage form
Route	Oral
Frequency	Once daily
Timing	Evening or nighttime
Daily dose	About 1,000 mg to about 3,000 mg
HPMC content	About 5% to about 50% by weight
Povidone content	About 1% to about 5% by weight
Stearic acid content	About 0.5% to about 2.0% by weight
Claimed lipid effects	Reduced total cholesterol, LDL cholesterol, triglycerides and Lp(a); increased HDL cholesterol

The four claims differ primarily by the amount of niacin in each dosage form:

Claim	Niacin per dosage form	Minimum practical number of units to reach 1,000 mg daily
1	About 375 mg	Three units provide about 1,125 mg
2	About 500 mg	Two units provide about 1,000 mg
3	About 750 mg	Two units provide about 1,500 mg
4	About 1,000 mg	One unit provides about 1,000 mg

The daily-dose limitation is separate from the dosage-unit limitation. A product containing 375 mg of niacin can fall within claim 1 only if the prescribed daily administration reaches approximately 1,000 mg to 3,000 mg.

How narrow are the U.S. Patent 7,998,506 claims?

The claims are narrow in formulation but potentially broad in administration.

A competing product must satisfy the specified excipient ranges in the administered dosage form. A formulation that contains niacin but lacks povidone, contains stearic acid outside the claimed range, or uses a different release matrix may avoid literal infringement.

The claims are potentially broad because they do not require:

A specific brand name;
A particular manufacturing process;
A specific tablet weight;
A particular particle size for niacin;
A specific dissolution profile;
A particular patient subgroup;
A named hyperlipidemia diagnosis;
Concomitant statin therapy;
A specific clinical threshold for LDL, HDL, triglycerides or Lp(a).

The claims also use “about,” which creates numerical latitude. The scope of that term would depend on the patent specification, prosecution history, relevant technical meaning and whether the proposed product is sufficiently close to the claimed concentration.

What formulations are protected by Patent 7,998,506?

The formulation limitations require three excipients:

Hydroxypropyl methylcellulose, also called HPMC, at about 5% to about 50% by weight;
Povidone at about 1% to about 5% by weight;
Stearic acid at about 0.5% to about 2.0% by weight.

HPMC is the principal controlled-release matrix component. Povidone may function as a binder or processing aid. Stearic acid may affect lubrication, matrix characteristics, release behavior or tablet processing.

The claims do not state that these are the only excipients. A qualifying product can therefore contain additional materials unless the specification, prosecution history or claim construction imposes a narrower interpretation.

Formulation design-around opportunities

Potential design-around strategies include:

Replacing HPMC with another release-controlling polymer;
Using HPMC outside the claimed concentration range;
Eliminating povidone or substituting another binder;
Using a different fatty acid or lubricant instead of stearic acid;
Changing the dosage form from a matrix tablet to a multiparticulate or coated-pellet system;
Altering the unit strength so that none of the four dosage-unit limitations applies;
Using immediate-release, delayed-release or another non-sustained-release formulation.

These approaches do not automatically avoid infringement. A product can still face an equivalent-infringement theory, induced-infringement allegations or separate infringement claims under related patents.

Does Patent 7,998,506 cover NIASPAN?

The claims closely track the clinical and labeling profile of extended-release niacin products such as NIASPAN. The FDA-approved NIASPAN labeling describes once-daily administration, generally at bedtime, and includes 500 mg, 750 mg and 1,000 mg extended-release tablets. The product is indicated for hyperlipidemia and dyslipidemia, including effects on LDL cholesterol, HDL cholesterol and triglycerides (U.S. Food and Drug Administration, 2019).

That alignment creates a substantial risk that an ANDA product with the same formulation architecture and labeling could be accused of practicing the claimed method.

Patent coverage should be separated into three categories:

Coverage category	Relevance to Patent 7,998,506
Product composition	Limited to the claimed niacin dosage form and excipient ranges
Method of use	Central subject matter; requires once-daily evening or nighttime dosing
Manufacturing process	Not claimed in the four claims supplied

A generic manufacturer could challenge the patent by arguing that its product does not contain the required excipients, does not meet the claimed ranges, does not have the required release characteristics, or is not labeled for evening or nighttime administration.

What is the Orange Book status of Patent 7,998,506?

The Orange Book analysis requires separating listing status from enforceability.

A patent may be listed for an approved drug if it claims the drug substance, drug product, formulation or an approved method of use. A method-of-use patent generally must correspond to a use described in approved labeling. Listing does not establish validity, enforceability or infringement.

For an ANDA applicant, an Orange Book-listed patent can produce one of four principal certifications:

Certification	Meaning
Paragraph I	No patent information has been submitted
Paragraph II	Patent has expired
Paragraph III	Applicant will wait until patent expiration
Paragraph IV	Patent is invalid, unenforceable or will not be infringed

A Paragraph IV notice can trigger Hatch-Waxman litigation under 35 U.S.C. § 271(e)(2). A timely infringement action by the patent holder can create a 30-month stay of ANDA approval, subject to statutory exceptions and court action (U.S. Congress, 1984).

The supplied claim text does not establish whether Patent 7,998,506 is currently listed in the Orange Book, whether it was delisted, or whether it has expired after patent-term adjustment or terminal-disclaimer review. Those determinations must be made from the FDA Orange Book record and the USPTO patent-term record, not from the claims alone.

When does Patent 7,998,506 lose exclusivity?

Patent expiration is determined by the patent’s earliest effective nonprovisional priority date, applicable patent-term adjustment, patent-term extension, terminal disclaimers and any intervening statutory changes.

The issue date, Aug. 30, 2011, does not determine the expiration date. For a standard utility patent filed after June 8, 1995, the base term is generally 20 years from the earliest effective nonprovisional filing date, subject to adjustment under 35 U.S.C. § 154.

The exclusivity analysis should therefore use two separate dates:

Exclusivity type	Legal source	Business effect
FDA drug exclusivity	Hatch-Waxman regulations and FDA approval history	Can delay approval even without an unexpired patent
Patent exclusivity	35 U.S.C. §§ 154 and 156	Can block approval or create litigation exposure
Commercial exclusivity	Market and contracting conditions	May persist after legal exclusivity ends

Patent 7,998,506 should not be treated as an active barrier solely because it appears in historical litigation or older Orange Book records. Its current enforceability requires confirmation through the USPTO Patent Center, Patent Examination Data System records, continuity data and terminal-disclaimer information.

Which companies are likely to challenge the patent?

The most likely challengers are ANDA applicants seeking approval for generic extended-release niacin tablets. Historically, the generic niacin market has included companies such as Teva, Sandoz, Watson/Actavis, Wockhardt and other manufacturers of oral solid-dose cardiovascular products.

The relevant challenger profile is a company whose ANDA product:

Uses a 500 mg, 750 mg or 1,000 mg extended-release niacin strength;
Has a label recommending once-daily or bedtime administration;
Uses HPMC, povidone and stearic acid;
Relies on the reference listed drug’s safety and efficacy data;
Seeks approval for the same hyperlipidemia indications.

A generic manufacturer may avoid a method-of-use patent through a section viii statement that omits the patented indication or dosing instruction, but that strategy is difficult where the patented use is embedded in the approved product’s principal labeling.

What Paragraph IV challenges and litigation issues matter?

A Paragraph IV challenge to Patent 7,998,506 would likely focus on:

Invalidity

Potential arguments include:

Anticipation by prior sustained-release niacin formulations;
Obviousness based on known niacin dosing, bedtime administration and controlled-release matrices;
Lack of written description for the full breadth of the excipient ranges;
Lack of enablement across the claimed formulation and dosage range;
Indefiniteness of “about,” “evening,” “night,” “sustained release” or “hyperlipidemic.”

The combination of excipient ranges and dosing timing may provide the patent holder with a narrower but more defensible obviousness position than a claim directed only to niacin treatment.

Noninfringement

A challenger would likely argue that its product:

Does not contain one or more required excipients;
Falls outside one or more concentration ranges;
Uses a different release system;
Is not labeled for nighttime administration;
Does not practice the claimed daily-dose range;
Does not satisfy the outcome limitations.

Induced infringement

Even where direct patient administration is the act that practices the method, a generic manufacturer can face induced-infringement allegations if its labeling encourages the patented regimen. The label, product monograph, promotional materials and physician instructions would be central evidence.

How strong is the patent estate for extended-release niacin?

Patent 7,998,506 is best viewed as one layer in a broader niacin product estate rather than a standalone composition patent.

Estate layer	Typical subject matter	Risk profile
Drug substance	Niacin itself	Minimal, because niacin is an old active ingredient
Release formulation	Matrix, coating, excipients and dissolution	Moderate to high if formulation matches the reference product
Dosage regimen	Once-daily, nighttime, titration and dose range	Moderate; label-dependent
Method of treatment	Lipid effects and patient population	Moderate, subject to proof and claim construction
Manufacturing	Granulation, compression and coating processes	Product-specific
Regulatory exclusivity	NDA exclusivity and pediatric extensions	Time-limited and separate from patent rights

The strongest infringement position arises when a proposed generic matches both the formulation and the labeled dosing regimen. The weakest position arises when the generic uses a materially different release technology and omits bedtime dosing from its label.

What generic launch scenarios exist?

At-risk launch

A generic may launch before final resolution of litigation after receiving FDA approval. This exposes the company to damages, an injunction and possible destruction or recall of inventory.

Delayed launch

The applicant may await patent expiration, a settlement date or a court judgment. This reduces litigation exposure but delays market entry.

Label carve-out

The applicant may seek approval with a section viii carve-out removing the patented method from labeling. This approach depends on whether the remaining indications and dosing instructions can support approval.

Formulation design-around

A company may develop a product outside the claimed excipient ranges or with a different sustained-release architecture. This raises development, bioequivalence and manufacturing-validation costs.

Is there biosimilar risk for Patent 7,998,506?

No. Niacin is a synthetic small-molecule active ingredient. Products competing with extended-release niacin are regulated through the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.

The relevant competitive risks are generic substitution, formulation design-arounds, authorized generic supply and potential therapeutic substitution by statins, fibrates, ezetimibe and newer lipid-lowering agents.

How does this patent compare with competing lipid-lowering products?

Product class	Active ingredient	Primary regulatory route	Patent risk relative to 7,998,506
Extended-release niacin	Niacin	ANDA for generics	Directly relevant
Statins	Atorvastatin, rosuvastatin and others	ANDA or NDA	Generally unrelated
PCSK9 inhibitors	Evolocumab, alirocumab	Biologics pathway	No direct overlap; biosimilar risk applies
Fibrates	Fenofibrate, gemfibrozil	ANDA or NDA	No direct claim overlap
Bempedoic acid	Bempedoic acid	NDA	Separate composition and method estate
Ezetimibe combinations	Ezetimibe with statins	ANDA or NDA	Separate formulation and combination claims

The commercial threat to NIASPAN is broader than Patent 7,998,506. Niacin competes with established generic statins and other lipid therapies whose prescribing patterns may reduce the addressable market even when niacin patents remain enforceable.

What licensing and settlement issues should be reviewed?

A complete commercial review should identify:

Patent licenses involving the original sponsor, Kos Pharmaceuticals, Abbott Laboratories or successor entities;
ANDA litigation settlements;
Authorized-generic arrangements;
Supply agreements for extended-release niacin;
Covenants not to sue;
Launch dates tied to patent expiration;
Royalty obligations and field-of-use restrictions.

The supplied claims do not identify any license, settlement, covenant, assignment history or litigation disposition. Those agreements can materially alter the practical exclusivity period and cannot be inferred from claim language.

Key Takeaways

Patent 7,998,506 claims a method, not niacin as a molecule.
The method requires sustained-release oral niacin, once daily, in the evening or at night.
The formulation must contain HPMC, povidone and stearic acid within specified ranges.
The claimed unit strengths are approximately 375 mg, 500 mg, 750 mg and 1,000 mg.
The total daily dose must be approximately 1,000 mg to 3,000 mg.
The patent is particularly relevant to NIASPAN-type extended-release niacin products.
A generic can attack the patent through Paragraph IV invalidity or noninfringement arguments.
A section viii label carve-out or formulation design-around may reduce infringement exposure.
The product is a small molecule, so biosimilar law is not relevant.
Current Orange Book listing, patent expiration and litigation status require record-level verification from FDA and USPTO sources.

FAQs

Can a 500 mg generic niacin tablet infringe Patent 7,998,506?

Yes, if the product is sustained release, contains the claimed excipients within the stated ranges, is labeled for once-daily evening or nighttime use, and is administered within the claimed daily-dose range.

Does a product infringe if it contains HPMC but no povidone?

It would not literally satisfy the supplied claims because povidone is a required claim element. The patent holder could still evaluate doctrine-of-equivalents theories.

Does the patent cover immediate-release niacin?

No. Each supplied claim requires a sustained-release solid oral dosage form.

Can a generic avoid the patent by using a 1,500 mg tablet?

Possibly, if the dosage form does not fall within the claimed 375 mg, 500 mg, 750 mg or 1,000 mg unit-strength limitations and no related patent covers the alternative strength.

Are the claimed lipid effects independently sufficient to establish infringement?

The effects are claim limitations, but infringement would generally be assessed against the complete claim. The formulation, dose, timing and treatment conditions must also be satisfied.

References

U.S. Patent No. 7,998,506. (2011). Methods of treating hyperlipidemia. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2019). NIASPAN prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, patent term adjustment and patent term extension provisions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	289197	⤷ Start Trial
Australia	4751802	⤷ Start Trial
Australia	6348198	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,998,506

Summary for Patent: 7,998,506